Research ArticleCancer

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

+ See all authors and affiliations

Science Translational Medicine  15 Mar 2017:
Vol. 9, Issue 381, eaaf2968
DOI: 10.1126/scitranslmed.aaf2968

You are currently viewing the editor's summary.

View Full Text

Brain tumors, meet macrophages

A protein called CD47 is often expressed on the surface of tumor cells, where it serves as a “don’t eat me” signal that blocks macrophages from attacking the tumor. To overcome this signal and allow the macrophages to “eat” tumor cells, Gholamin et al. engineered a humanized antibody that blocks CD47 signaling. The researchers tested the efficacy of this antibody in patient-derived xenograft models of a variety of pediatric brain tumors. The treatment was successful at inhibiting CD47, killing tumor cells, and prolonging the animals’ survival, all without toxic effects on normal tissues.